Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4218243 | 0.81 | PDPK1 (0.32) | PDPK1 | |
| SCHEMBL16591438 | 0.78 | PDPK1 (0.41) | PDPK1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6792619 | 0.73 | AGXT (0.38) | PDPK1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5649291 | 0.73 | NOS2 (0.44) | ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL6794146 | 0.73 | HPGD (0.42) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4536423 | 0.72 | PDPK1 (0.43) | PDPK1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL25463299 | 0.71 | PDPK1 (0.36) | PDPK1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL22139947 | 0.70 | PDPK1 (0.35) | PDPK1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL22139943 | 0.70 | HSD17B10 (0.38) | PDPK1MAPTALDH1A1LMNAHSD17B10 | |
| SCHEMBL19762502 | 0.70 | PRKCQ (0.34) | PDPK1KMT2ALMNAHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523277-B1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE OVERSEAS SARL (LU) | 2021-06-30 | — | — | EP | disclosed |
| US-20190315687-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-10-17 | — | — | US | disclosed |
| US-10399940-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-09-03 | — | — | US | disclosed |
| EP-3523277-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | GALAPAGOS NV (BE) | 2018-04-12 | — | — | US | disclosed |
| WO-2018065921-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE S.Á.R.L. (LU) | 2018-04-12 | — | — | WO | disclosed |
| US-20090053137-A1 | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof | SpecGx LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090053137-A1 | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof | SpecGx LLC | 2009-02-26 | — | — | US | disclosed |
| WO-2007106544-A2 | CHELATING CONJUGATES HAVING A SUBSTITUTED AROMATIC MOIETY AND DERIVATIVES THEREOF | MALLINCKRODT INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20040116480-A1 | Oxime ether compound and agricultural or horticultural bactericide | NIPPON SODA CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1362850-A1 | OXIME ETHER COMPOUND AND AGRICULTURAL OR HORTICULTURAL BACTERICIDE | NIPPON SODA CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053137-A1 | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof | SLC30A5, SLC40A1, SLC46A1 | PDPK1 4677/4885MAPT 1650/4885ALDH1A1 905/4885 |
| US-20190315687-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | PDPK1 2672/4885MAPT 4871/4885ALDH1A1 563/4885 |
| US-10399940-B2 | Substituted pyrrolidines and methods of use | CFTR, PKD1, PKD2 | PDPK1 2672/4885MAPT 4871/4885ALDH1A1 563/4885 |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | PDPK1 2672/4885MAPT 4871/4885ALDH1A1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.